Corneal graft rejection is a condition where the body’s immune system attacks donor corneal tissue after a transplant, potentially threatening restored vision. While the cornea benefits from some natural immune protection, rejection remains the leading cause of transplant failure, requiring prompt recognition and specialized treatment to preserve the graft and maintain clear sight.

Why Understanding Treatment Matters After Corneal Transplant

When someone receives a corneal transplant, they regain the gift of sight through donor tissue that replaces their damaged or diseased cornea. The main goals of managing corneal graft rejection focus on preserving the transplanted tissue, maintaining clear vision, and preventing complete graft failure. Treatment approaches vary significantly depending on how severe the rejection episode is, how quickly it’s detected, and whether the patient has risk factors that make rejection more likely.^[1]

The cornea occupies a unique position among transplanted organs. It benefits from what doctors call “immune privilege,” meaning it naturally faces less aggressive attack from the body’s defense system compared to other transplanted organs. Despite this advantage, the immune system can still recognize the donor tissue as foreign and mount an attack against it. This process represents the most common reason why corneal transplants fail over time.^[2]

For patients receiving their first corneal transplant with no blood vessels growing into their cornea, success rates exceed 90% at two years. However, when certain risk factors are present—such as previous rejection, inflammation, or blood vessel growth in the cornea—this success rate drops dramatically to between 35% and 70%. Understanding these numbers helps explain why some patients require more intensive preventive treatment than others.^[1]

Medical societies and eye care specialists have developed standard treatment protocols based on decades of experience and research. These established approaches form the foundation of care, but researchers continue exploring new therapies through clinical trials. Some patients benefit from conventional treatments using corticosteroid medications, while others with high-risk transplants may need combinations of drugs or participation in studies testing innovative approaches to prevent rejection.^[7]

Standard Treatment Approaches for Corneal Graft Rejection

When corneal graft rejection occurs, topical corticosteroids—steroid medications applied directly to the eye surface—form the cornerstone of treatment in all cases. These medications work by suppressing the immune system’s inflammatory response against the donor tissue. The specific drug, frequency of application, and duration of treatment depend on what type of rejection is happening and how severe it appears.^[7]

For milder forms of rejection affecting only the outer layers of the cornea, doctors typically prescribe topical corticosteroid drops such as dexamethasone 0.1% or prednisolone acetate 1%. Patients apply these medications four to six times daily until the signs of rejection resolve. This usually takes several weeks, after which the doctor slowly reduces the frequency over time. These epithelial or stromal rejections generally don’t progress to complete graft failure if caught early, but they signal that the immune system has recognized the donor tissue and could mount a more serious attack later.^[7]

The most concerning type of rejection targets the endothelial cells—the innermost layer of cells that pump fluid out of the cornea to keep it transparent. Because human endothelial cells cannot multiply or regenerate, losing too many of these cells results in permanent corneal swelling and cloudiness. When endothelial rejection occurs, treatment must be far more aggressive. Doctors instruct patients to use corticosteroid drops every hour while awake and as frequently as possible during the night for the first two to three days. After this intensive period, the schedule shifts to every two hours while awake. Some specialists prescribe higher-potency steroids like difluprednate for severe cases.^[7]

Steroid ointment may be added at bedtime to provide continuous medication coverage overnight. This intensive regimen continues until clinical examination shows the rejection signs are resolving. The tapering process then occurs slowly over several weeks to months, carefully adjusted based on the patient’s response. Doctors recommend continuing treatment for at least four weeks even if no improvement appears, before determining the graft has failed irreversibly.^[7]

For severe endothelial rejection, recurrent rejection episodes, or patients at high risk—such as those with chemical burns or extensive blood vessel growth in their cornea—doctors may add other routes of steroid administration. Subconjunctival injection involves injecting steroids like dexamethasone phosphate (2 mg) or betamethasone (3 mg) directly under the conjunctiva, the clear tissue covering the white of the eye. This creates a local reservoir of medication at high concentration near the cornea.^[7]

Another option involves placing a collagen shield soaked in corticosteroids directly on the cornea. This device acts like a slow-release drug delivery system, steadily releasing medication between the times when patients apply their eye drops. This approach intensifies local steroid concentration without requiring more frequent drop administration.^[7]

In cases of severe endothelial rejection or when patients face particularly high risk of graft loss, doctors may prescribe systemic steroids or immunosuppressants—medications taken by mouth or through intravenous infusion that affect the entire body’s immune system. Oral prednisone typically starts at dosages of 60 to 80 milligrams daily, continuing for one to two weeks before gradually tapering down. However, treatment practices vary widely among surgeons, and these decisions depend largely on individual clinical judgment.^[7]

Research has shown that pulsed steroids—a single intravenous dose of 500 milligrams of methylprednisolone—can improve graft survival rates compared to oral steroids, particularly when administered early in a rejection episode (within the first eight days). This approach also reduces the risk of future rejection episodes, which represents an important benefit for high-risk grafts. Pulsed steroids offer the advantage of avoiding prolonged oral steroid use, which carries more side effects.^[7]

Regardless of which treatment approach is used, monitoring intraocular pressure (pressure inside the eye) is essential. Corticosteroids can raise eye pressure in susceptible individuals, potentially causing glaucoma damage. Doctors check pressure regularly during intensive steroid treatment and add pressure-lowering medications if needed.^[7]

For patients at high risk of rejection from the outset, preventive treatment becomes crucial. Some specialists prescribe long-term use of topical immunosuppressive agents such as cyclosporine or tacrolimus (FK506). These drugs suppress specific parts of the immune response without the side effects associated with long-term steroid use. Studies have examined their effectiveness in preventing rejection in high-risk patients, though practices vary among different medical centers.^[6]

Side effects from topical corticosteroids, when used intensively or long-term, can include elevated eye pressure leading to glaucoma, cataract formation, increased risk of eye infections, delayed wound healing, and thinning of the cornea. Systemic steroids carry additional risks including weight gain, mood changes, elevated blood sugar, bone loss, and increased infection susceptibility. Doctors must balance these risks against the urgent need to save the graft.^[7]

Clinical guidelines emphasize the importance of patient education and compliance. Missing doses during a rejection episode can allow the immune attack to progress irreversibly. Similarly, abruptly stopping medications after successful treatment of rejection can trigger a rebound immune response. The tapering schedule must be followed carefully, even though it extends over months and requires diligent attention.^[12]

Innovative Therapies in Clinical Research

While standard corticosteroid-based treatment successfully reverses many rejection episodes, researchers recognize that some patients—particularly those with multiple risk factors—need additional strategies. Clinical trials are investigating several promising approaches to prevent and treat corneal graft rejection through new mechanisms that complement or replace conventional therapies.^[11]

One area of active research focuses on combinations of systemic immunosuppressive agents used successfully in other organ transplants. Studies have examined protocols using oral prednisone combined with azathioprine and cyclosporine in high-risk corneal transplant patients. Azathioprine is an antimetabolite—a drug that interferes with DNA synthesis in rapidly dividing immune cells, thereby reducing their ability to attack the graft. Cyclosporine belongs to a class called calcineurin inhibitors, which block specific signals that activate T cells, the immune cells primarily responsible for graft rejection.^[11]

In a case series following three patients who had previously lost grafts to rejection, researchers used a tailored combination of these three agents to prevent rejection in repeat corneal transplants. Over a mean follow-up period of 37 months, all grafts remained clear with minimal adverse effects. This multi-agent approach aims to use lower doses of each medication, potentially reducing side effects while maintaining immune suppression. These studies represent Phase II and Phase III level research, examining both efficacy and comparing outcomes with standard treatment approaches.^[11]

The mechanism behind combination immunosuppression involves targeting multiple points in the immune response pathway. Prednisone broadly suppresses inflammation and immune cell activity. Azathioprine specifically reduces proliferation of lymphocytes that would otherwise attack foreign tissue. Cyclosporine prevents T cell activation by blocking interleukin-2 production, a critical signal for mounting immune responses. By hitting the immune system at multiple points simultaneously, this strategy may provide more reliable protection than any single agent alone.^[11]

Another innovative direction involves treating the donor tissue itself before transplantation. Researchers at Massachusetts Eye and Ear developed a technique exposing donor corneas to a cocktail of cytokines—signaling molecules that regulate immune responses. Specifically, they used transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10), two cytokines that promote immune tolerance rather than activation. This pre-treatment changes the function of antigen-presenting cells in the donor cornea, making them more likely to induce tolerance in the recipient’s immune system rather than triggering rejection.^[18]

In preclinical models representing high-risk transplant conditions, this approach significantly improved outcomes. Eight weeks after transplantation, nearly 69% of treated grafts survived, while none of the control grafts remained clear. This early-phase research (Phase I/II level) demonstrated safety and preliminary efficacy. The technique represents a fundamentally different strategy—modifying the donor tissue to be “immune-friendly” rather than suppressing the recipient’s immune system. If proven effective in human trials, this could reduce or eliminate the need for prolonged immunosuppressive therapy after transplant.^[18]

The researchers determined optimal doses, concentrations, and exposure times needed for the cytokine cocktail to effectively generate tolerance-inducing cells in corneal tissue. This precision matters because too little treatment wouldn’t provide benefit, while excessive exposure could damage the donor tissue. The goal is making corneal transplantation safer and more successful for the one-third of cases considered high-risk, where conventional approaches often fail.^[18]

Clinical trials are also examining various protocols for preventing rejection using topical immunosuppressive agents applied after transplant but before any rejection occurs. Studies have tested cyclosporine A 2% eye drops in preventing rejection in high-risk patients. This represents Phase III research comparing outcomes between patients receiving cyclosporine prevention versus standard care alone. The mechanism involves direct suppression of local immune responses at the graft site without significant systemic effects.^[12]

Researchers continue investigating optimal timing and duration for preventive treatments. Some protocols begin immunosuppressive therapy immediately after transplant and continue for months or years. Others reserve additional agents for patients showing early warning signs of immune activation. These studies often take place at major medical centers in the United States, Europe, and other regions with advanced ophthalmology research programs.^[12]

Patient eligibility for these trials typically requires specific risk factors such as previous graft rejection, extensive corneal vascularization (blood vessel growth), severe ocular surface disease, multiple previous transplants, or inflammatory eye conditions. Participants must meet criteria regarding overall health status, ability to comply with complex medication schedules, and willingness to attend frequent monitoring visits. Trial protocols specify detailed inclusion and exclusion criteria that determine who can participate.^[11]

Preliminary results from various trials show promise for reducing rejection rates and improving long-term graft survival in high-risk populations. Some studies report rejection rates as low as 6% to 15% with newer surgical techniques and optimized immunosuppression protocols, compared to historical rates of 30% or higher. However, these remain investigational approaches requiring further validation before becoming standard practice.^[2]

An important consideration in clinical research involves understanding different types of corneal transplant procedures. Penetrating keratoplasty (PKP), which replaces the full thickness of the cornea, carries higher rejection risk than newer partial-thickness procedures. Deep anterior lamellar keratoplasty (DALK) replaces only the outer layers while preserving the patient’s own endothelial cells, significantly reducing rejection rates to 6% to 20% compared to full-thickness grafts. Descemet stripping endothelial keratoplasty (DSEK/DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) replace only the innermost layer, also showing lower rejection rates than traditional PKP.^[2]

Research into synthetic or bioengineered corneal alternatives aims to eventually eliminate rejection entirely by using materials the immune system doesn’t recognize as foreign tissue. While still in early investigational phases, these approaches represent the ultimate goal—restoring vision without the need for immunosuppression or risk of rejection. Such technologies remain years away from widespread clinical use but demonstrate the breadth of research efforts addressing this challenge.^[2]

Most common treatment methods

• Topical corticosteroid therapy
  • Dexamethasone 0.1% eye drops applied four to six times daily for mild to moderate rejection, or every hour for severe endothelial rejection
  • Prednisolone acetate 1% drops used similarly, with frequency depending on rejection severity
  • Difluprednate, a higher-potency steroid option for severe or resistant cases
  • Steroid ointment applied at bedtime to provide overnight medication coverage
  • Slow tapering over weeks to months after rejection resolves to prevent rebound immune response
• Injectable corticosteroid administration
  • Subconjunctival injection of dexamethasone phosphate 2 mg or betamethasone 3 mg directly near the cornea
  • Creates local high-concentration drug reservoir for severe or recurrent rejection
  • Used in conjunction with intensive topical therapy in high-risk cases
• Systemic corticosteroid therapy
  • Oral prednisone 60-80 mg daily for one to two weeks, then gradually tapered
  • Intravenous methylprednisolone 500 mg as single pulsed dose for early, severe rejection
  • Pulsed therapy shown to improve graft survival and reduce future rejection episodes compared to oral steroids
  • Reserved for severe endothelial rejection or high-risk patients
• Topical immunosuppressive agents
  • Cyclosporine A 2% eye drops for prevention in high-risk patients
  • Tacrolimus (FK506) drops as alternative immunosuppressive option
  • Long-term use to suppress local immune responses without systemic steroid side effects
  • Studied particularly for patients who cannot tolerate long-term topical steroids
• Combination systemic immunosuppression
  • Triple therapy using oral prednisone, azathioprine, and cyclosporine together
  • Multi-agent approach targeting different immune pathways simultaneously
  • Used in clinical trials and specialized centers for high-risk repeat transplants
  • Requires careful monitoring for drug interactions and side effects
• Novel cytokine pre-treatment
  • Treating donor corneal tissue with TGF-β and IL-10 cocktail before transplantation
  • Modifies donor tissue to promote tolerance rather than rejection
  • Under investigation in clinical research settings
  • Aims to reduce need for long-term immunosuppression in recipients
• Collagen shield drug delivery
  • Collagen shield soaked in corticosteroids placed directly on cornea
  • Acts as slow-release reservoir providing continuous medication between drop applications
  • Combined with frequent topical drops for severe rejection episodes